Cannabix Technologies (BLO) AI Stock Analysis

• Market Cap: C$75.07M
• Dividend Yield: N/A
• Average Volume (3M): 36.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: N/A
• EPS Growth: -52.41%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 121,074,104
• 10 Day Avg. Volume: 30,616
• 30 Day Avg. Volume: 36,452
• PEG Ratio: -0.30
• Price to Book (P/B): 27.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -37.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.55 ▼(-8.50% Downside)

The score is primarily held down by very weak financial performance (minimal revenue, large losses, and ongoing cash burn) despite low leverage. Technical indicators are modestly supportive in the near term, but valuation is constrained by negative earnings and no dividend data.

Cannabix Technologies Business Overview & Revenue Model

Company Description

Cannabix Technologies Inc., a technology company, develops marijuana breathalyzer for employers, law enforcement, governments, and public in North America. It develops tetrahydrocannabinol breath analyzers, a point of care breath testing tool for the rapid detection of recent cannabis use, as well as breath collection units. The company was formerly known as West Point Resources Inc. and changed its name to Cannabix Technologies Inc. in August 2014. Cannabix Technologies Inc. was incorporated in 2011 and is based in Burnaby, Canada.

How the Company Makes Money

Cannabix Technologies makes money primarily through the development and sale of its breathalyzer devices designed to detect cannabis usage. Revenue is generated from the sales of these devices to law enforcement agencies, employers, and other entities interested in cannabis detection technology. The company may also have potential revenue streams from licensing its technology to other firms and entering into strategic partnerships for distribution and development. However, specific data on these activities is not available.

Cannabix Technologies Financial Statement Overview

Summary

Financials indicate an early-stage/high-risk profile: revenue is effectively zero, gross profit is negative, losses are widening (net income down to about -$4.7M in 2025), and cash burn persists (operating cash flow about -$1.8M in 2025). Low leverage is a positive, but equity has fallen sharply, reducing financial flexibility.

Income Statement

Financial performance remains very weak. Revenue is effectively zero in most years (including 2022–2025), while losses are persistent and sizable, with net income deteriorating from -$2.1M (2023) to -$3.1M (2024) and -$4.7M (2025). Gross profit is negative across the period, pointing to an unfavorable cost structure and limited operating leverage at the current scale.

Balance Sheet

Leverage is low, which is a clear positive (debt-to-equity ~0.06 in 2025). However, the equity base has shrunk sharply from ~$10.3M (2021) to ~$2.6M (2025), reflecting ongoing losses and potential dilution/erosion of capital. Returns on equity are deeply negative (about -184% in 2025), highlighting that the balance sheet is being consumed by continuing unprofitability despite modest debt levels.

Cash Flow

Cash generation is consistently negative, with operating cash flow at about -$1.8M in 2025 (also negative in prior years) and free cash flow remaining meaningfully negative across the entire period. Free cash flow worsened year-over-year in 2025 (roughly -9% growth), reinforcing continued cash burn and dependence on external funding to sustain operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	6.57M
Gross Profit	-168.52K	-153.24K	-126.29K	-29.22K	-25.57K
EBITDA	-4.55M	-2.96M	-2.01M	-3.11M	-9.11M
Net Income	-4.69M	-3.13M	-2.14M	-3.37M	-9.24M
Balance Sheet
Total Assets	3.00M	4.70M	6.95M	8.76M	10.38M
Cash, Cash Equivalents and Short-Term Investments	2.35M	4.26M	6.52M	8.45M	10.10M
Total Debt	158.65K	154.58K	132.54K	0.00	0.00
Total Liabilities	447.71K	248.02K	237.17K	120.84K	80.78K
Stockholders Equity	2.55M	4.45M	6.71M	8.64M	10.30M
Cash Flow
Free Cash Flow	-1.86M	-2.11M	-2.00M	-2.13M	-1.79M
Operating Cash Flow	-1.84M	―	-1.97M	-2.13M	-1.71M
Investing Cash Flow	-17.54K	-30.96K	-28.65K	-4.59K	-121.81K
Financing Cash Flow	-58.47K	-143.53K	10.88K	492.50K	3.49M

Cannabix Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLO, the sentiment is Positive. The current price of 0.6 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.55, and above the 200-day MA of 0.58, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 64.68 is Neutral, neither overbought nor oversold. The STOCH value of 80.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BLO.

Cannabix Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QIPT	70 Outperform	C$216.62M	-14.25	-10.51%	―	2.48%	-53.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VPT	50 Neutral	C$22.64M	-5.65	―	―	28.59%	23.46%
BLO	46 Neutral	C$75.07M	-11.48	-188.03%	―	―	-52.41%
PINK	46 Neutral	C$37.22M	-1.62	-181.70%	―	209.29%	35.38%
PMED	46 Neutral	C$11.37M	-7.25	―	―	―	9.21%

Cannabix Technologies Corporate Events

Cannabix Wins First International BreathLogix Order, Scraps Planned Financing

Cannabix Technologies has secured its first international distributor order for its BreathLogix autonomous alcohol screening devices and accessories from its exclusive Australian partner, Breathalyser Sales & Service Pty Ltd, covering Australia, New Zealand and the Pacific Islands. The BreathLogix system offers rapid pre-access breath alcohol checks, identity-confirming photos, real-time alerts and cloud-based reporting, and can be integrated with site access controls and fleet management systems, positioning it for deployment across industries such as mining, oil and gas, industrial and logistics. Featuring a patent-pending pre-calibrated sensor cartridge to simplify maintenance, the product launch momentum has prompted Cannabix to cancel a planned non-brokered private placement and reassess its near-term capital needs in early 2026, while the company also initiates a short investor awareness campaign to broaden market visibility.

The most recent analyst rating on (TSE:BLO) stock is a Hold with a C$0.59 price target. To see the full list of analyst forecasts on Cannabix Technologies stock, see the TSE:BLO Stock Forecast page.

Cannabix Technologies’ Marijuana Breath Test Achieves Key Regulatory Milestone

Cannabix Technologies Inc. announced a significant milestone for its Marijuana Breath Test (MBT) system as its Breath Collection Unit (BCU) passed the Federal Communications Commission’s electronic emissions testing. This achievement is crucial for the system’s commercialization in the U.S. and Canadian markets, where the company is completing necessary regulatory steps. The MBT system, which includes proprietary Breath Cartridges, is designed to collect and preserve breath samples for analysis, and Cannabix is working with Omega Laboratories to advance its commercialization. The successful emissions testing positions Cannabix favorably in the market, potentially impacting stakeholders by advancing the availability of reliable marijuana testing technology.

Cannabix Technologies Expands Maritime Market with Repeat BreathLogix Order

Cannabix Technologies has secured a second sales agreement for its BreathLogix unmanned alcohol screening technology with a European maritime shipping customer. This agreement involves the delivery of an additional BreathLogix unit to enhance crew safety through pre-access breath alcohol testing, integrated with the cloud-based BreathLogix Connect platform for real-time alerts and data management. The device also features facial recognition for secure identification and is designed for deployment across various industries where safety is paramount.

Cannabix Technologies Launches Private Placement to Raise Up to $2 Million

Cannabix Technologies announced a non-brokered private placement to raise between $1 million and $2 million through the issuance of units, each comprising one common share and a half warrant. The funds will be used for manufacturing, marketing, and general expenses. The placement includes an acceleration clause for warrants and involves participation from company insiders, with regulatory exemptions applied.

Cannabix Technologies Secures Patent for Contactless Breath Analysis Innovation

Cannabix Technologies Inc. has been granted a patent by the United States Patent and Trademark Office for its innovative contactless breath analysis technology. This advancement, integrated into their BreathLogix device, offers fast and reliable testing without physical contact, making it suitable for use in vehicles, workplaces, and public kiosks. The technology’s compact and modular design is particularly beneficial for applications in law enforcement, workplace safety, and public health monitoring, thereby strengthening Cannabix’s leadership in breath sampling and detection.

Cannabix Technologies Grants Incentive Stock Options

Cannabix Technologies Inc. has announced the granting of 2,500,000 incentive stock options to certain directors and consultants, with varying expiration terms. This move is part of the company’s stock option plan and aligns with CSE policies, potentially impacting the company’s operational strategy and stakeholder interests by incentivizing key personnel.

Cannabix Technologies Expands Safety Solutions with BreathLogix Deployment

Cannabix Technologies has delivered its BreathLogix alcohol screening device to an oil and gas transportation services company in northern Alberta, Canada. The BreathLogix system, designed for rapid and unmanned testing, enhances safety by providing precise Blood Alcohol Content levels and real-time alerts to managers. This adoption highlights Cannabix’s dedication to innovative safety solutions and strengthens its market position. Additionally, the company has engaged Black Swan Solutions Inc. for a digital marketing campaign to enhance its online presence.